Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The incidence of thyroid cancer has increased very rapidly in Korea; however, most previous studies suggested that the mortality rate for thyroid cancer remained stable. The objective of the current study was to evaluate recent changes in standardized thyroid cancer mortality using data from Statistics Korea.

Methods: Population and mortality data from 1985 through 2015 were obtained from Statistics Korea. Age-standardized mortality rates (ASMRs) from thyroid cancer per 100,000 population were calculated based on the World Health Organization standard population.

Results: In Korea, the ASMRs from thyroid cancer increased from 0.17 (95% confidence interval [CI], 0.17-0.18) per 100,000 in 1985 to 0.85 (95% CI, 0.83-0.86) per 100,000 in 2004, which was the highest among all countries. Subsequently, the ASMRs continuously decreased to 0.42 (95% CI, 0.41-0.43) per 100,000 between 2004 and 2015. The estimated annual percent change (APC) from 1985 to 2004 was 7.94 (95% CI, 6.43-9.46), and the corresponding value from 2004 to 2015 was -4.10 (95% CI, -5.76 to -2.40). Changes in the ASMRs reflected similar patterns in men (1985-2003: APC, 8.51; 2003-2015: APC, -4.32) and women (1985-2004: APC, 7.62; 2004-2015: APC, -4.38) and were also observed in older patients (aged ≥ 55 years).

Conclusions: Thyroid cancer mortality in Korea increased until 2004 and then continuously decreased until 2015. Increases in the early diagnosis of thyroid cancer, changes in exposure to risk factors, and standardization in diagnosis and treatment may be associated with the decrease in thyroid cancer mortality in Korea. Cancer 2017; 123:4808-14. © 2017 American Cancer Society.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30943DOI Listing

Publication Analysis

Top Keywords

thyroid cancer
36
cancer mortality
12
cancer
11
thyroid
9
changes standardized
8
mortality rates
8
1985 2015
8
cancer increased
8
mortality data
8
asmrs thyroid
8

Similar Publications

Myoepithelial Carcinoma Ex-Pleomorphic Adenoma Exposing a RET Germline Mutation: A Rare Genetic Event.

Head Neck Pathol

September 2025

Department of Laboratory Medicine and Pathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Myoepithelial carcinoma (MECA) is a malignant neoplasm composed exclusively of myoepithelial cells and accounts for less than 1% of all salivary gland tumors. Its diagnosis is often challenging due to histologic overlaps with benign lesions and its variable morphologic presentation. Although molecular profiling has emerged as a valuable tool in salivary gland tumor classification, the genetic landscape of MECA remains incompletely defined.

View Article and Find Full Text PDF

Cancer-associated fibroblasts as a potential therapeutic target for thyroid cancers.

Int J Surg

September 2025

BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Sciences, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.

Thyroid cancer, a prevalent endocrine malignancy, is influenced by its tumor microenvironment (TME), with cancer-associated fibroblasts (CAFs) playing a pivotal role in disease progression. Molecularly, CAFs orchestrate a pro-tumorigenic niche via cytokine secretion and extracellular matrix (ECM) stiffening, underscoring their targetability. Therapeutic strategies, including small molecule inhibitor-based therapies, immune-based therapies, nanoparticle-based approaches, and combination regimens, have been evaluated for their efficacy in disrupting CAF functionality.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) is an aggressive and challenging subtype of breast cancer, presenting patients with a more complex treatment journey. This underscores the critical need for ongoing research and the development of effective therapies to enhance patient outcomes. Signal transducer and activator of transcription 3 (STAT3) is a crucial transcription factor that regulates various cellular processes, including proliferation, survival, and immune modulation.

View Article and Find Full Text PDF

This dataset focuses on N6-Methyladenosine (m6A) RNA methylation in papillary thyroid carcinoma (PTC) without autoimmune thyroid disease (AITD). Emerging evidence suggests that m6A modification was associated with the occurrence and progression of both thyroid carcinoma and AITD. Given the substantial clinical overlap between thyroid carcinoma (particularly PTC) and AITD, rigorous exclusion of autoimmune confounding factors is essential to isolate the distinct role of m6A modifications in driving thyroid carcinogenesis and progression.

View Article and Find Full Text PDF

Thyroid carcinoma is among the most common endocrine system malignancies. Lactate metabolism and lactylation modification roles in carcinogenesis and development have garnered more interest in recent years. The expression and function of lactate transporters (MCTs) and significant metabolic enzymes are included in our summary of the characterisation of lactate metabolism in thyroid cancer.

View Article and Find Full Text PDF